PCSK9 and familial hypercholesterolemia: PCSK9 mAbs, Evolocumab, Alirocumab, and Inclisiran, were approved for clinical usage shortly after their discovery and have since been extensively utilized not only for treating familial hypercholesterolemia (FH) but also for secondary prevention of atherosclerotic cardiovascular disease (ASCVD) [10].